Tags

Type your tag names separated by a space and hit enter

Emerging diabetes therapies and technologies.
Diabetes Res Clin Pract. 2012 Jul; 97(1):16-26.DR

Abstract

The prevalence of diabetes is increasing globally and is expected to increase to 439 million people by the year 2030. Several studies have shown that improved glycemic control measured by glycosylated hemoglobin (A1c) in patients with type 1 and type 2 diabetes results in a reduction of both the micro- and macrovascular complications associated with the disease. The recent introduction of new oral medications, insulin analogs (long and rapid acting), insulin pens and pumps, better SMBG meters and continuous glucose monitoring (CGM) have all resulted in improvement of glycemic control. Closed-loop devices currently in development aim to integrate the CGM and pump system in order to more closely mimic the human pancreas. The other upcoming new basal insulin (Degludec), prandial insulin, other new technologies and improved oral therapies will significantly improve patient acceptance of intensive therapy, glycemic control and quality of life in patients with diabetes.

Authors+Show Affiliations

School of Medicine, University of Colorado Denver, Aurora, CO 80045, United States.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22381908

Citation

Moser, Emily G., et al. "Emerging Diabetes Therapies and Technologies." Diabetes Research and Clinical Practice, vol. 97, no. 1, 2012, pp. 16-26.
Moser EG, Morris AA, Garg SK. Emerging diabetes therapies and technologies. Diabetes Res Clin Pract. 2012;97(1):16-26.
Moser, E. G., Morris, A. A., & Garg, S. K. (2012). Emerging diabetes therapies and technologies. Diabetes Research and Clinical Practice, 97(1), 16-26. https://doi.org/10.1016/j.diabres.2012.01.027
Moser EG, Morris AA, Garg SK. Emerging Diabetes Therapies and Technologies. Diabetes Res Clin Pract. 2012;97(1):16-26. PubMed PMID: 22381908.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Emerging diabetes therapies and technologies. AU - Moser,Emily G, AU - Morris,Audrey A, AU - Garg,Satish K, Y1 - 2012/02/29/ PY - 2011/06/21/received PY - 2012/01/23/accepted PY - 2012/3/3/entrez PY - 2012/3/3/pubmed PY - 2012/12/10/medline SP - 16 EP - 26 JF - Diabetes research and clinical practice JO - Diabetes Res Clin Pract VL - 97 IS - 1 N2 - The prevalence of diabetes is increasing globally and is expected to increase to 439 million people by the year 2030. Several studies have shown that improved glycemic control measured by glycosylated hemoglobin (A1c) in patients with type 1 and type 2 diabetes results in a reduction of both the micro- and macrovascular complications associated with the disease. The recent introduction of new oral medications, insulin analogs (long and rapid acting), insulin pens and pumps, better SMBG meters and continuous glucose monitoring (CGM) have all resulted in improvement of glycemic control. Closed-loop devices currently in development aim to integrate the CGM and pump system in order to more closely mimic the human pancreas. The other upcoming new basal insulin (Degludec), prandial insulin, other new technologies and improved oral therapies will significantly improve patient acceptance of intensive therapy, glycemic control and quality of life in patients with diabetes. SN - 1872-8227 UR - https://www.unboundmedicine.com/medline/citation/22381908/Emerging_diabetes_therapies_and_technologies_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0168-8227(12)00053-8 DB - PRIME DP - Unbound Medicine ER -